Christie Schumacher PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP, joins The Huddle to talk through the use of GLP-1 and GIP/GLP-1 receptor agonists for your people with type 2 diabetes.  You’ll learn what medications fall into the class of GLP-1 and GIP/GLP-1 receptor agonists, how they work and the benefits they can offer people with type 2 diabetes. These medications can be a useful tool in the therapeutic toolkit as highlighted in the recently updated ADA/EASD consensus statement, so this episode will offer practical considerations when initiating GLP-1 and GIP/GLP-1 receptor agonists in patients and managing possible side effects.

We want to thank our sponsor, Lilly Diabetes, for their support of this episode.
VV-MED-128766 ©2022 Lilly USA, LLC.  All rights reserved

Resources:

• ADA and EASD Consensus Report for the Management of Hyperglycemia in Type 2 Diabetes, 2022:  Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | Diabetes Care | American Diabetes Association (diabetesjournals.org)
• ADCES Incretin-Based therapies tip sheet: DiabetesEducator.org/docs/default-source/living-with-diabetes/tip-sheets/medication-taking/incretin-based_therapies_tip_sheet_1006202291a90b03-fff9-4b81-98c9-42ef98f0c501.pdf
• Episode Transcript: DiabetesEducator.org/docs/default-source/podcast-docs/incretin-full-show.docx

Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.

Learn more about ADCES and the many benefits of membership at adces.org/join.